FDA May Request "Intermediate" Enforcement Authority For Clinical Trials
Executive Summary
FDA is considering asking Congress for authority to bring intermediate enforcement actions in response to violations of human research regulations in clinical trials, FDA Office of Regulatory Affairs Director of Enforcement Daniel Michels told the House Government Reform/Human Resources Subcommittee May 3.
You may also be interested in...
FDA Civil Penalties For Human Subject Violations Considered By Kennedy
Legislation granting FDA the authority to levy civil monetary penalties against researchers and institutions violating federal human subjects protections could be introduced by Sen. Kennedy (D-Mass.) before the end of the year.
FDA Civil Penalties For Human Subject Violations Considered By Kennedy
Legislation granting FDA the authority to levy civil monetary penalties against researchers and institutions violating federal human subjects protections could be introduced by Sen. Kennedy (D-Mass.) before the end of the year.
Trial Recruiting, IRBs Could Be Upcoming Congressional Hearing Topics
A hearing to discuss FDA and NIH progress in complying with HHS Inspector General recommendations on institutional review boards is being planned for early May by House Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee Chairman Mica (R-Fla.).